Keros Therapeutics Inc. shares lost over three-quarters of their market capitalization on Thursday, marking an all-time low, after the company halted two high-dose arms in its Phase 2 TROPOS trial of ...

While not a mind-blowing move, it is good to see that the Keros Therapeutics, Inc. (NASDAQ:KROS) share price has gained 12% in the last three months. But that isn't much consolation for the painful ...

Keros Therapeutics shareholder ADAR1 Capital Management said it plans to withhold votes for board members Mary Ann Gray and Alpna Seth. "ADAR1 calls for Keros to restructure the business, ...

Urges Stockholders to Protect Their Investment by Voting “FOR” the Company’s Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”, ...

Keros Therapeutics Inc (NASDAQ:KROS) released topline data from the TROPOS Phase 2 trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial ...

BTIG downgraded Keros Therapeutics (KROS) to Neutral from Buy after dosing in higher dose cohorts of the TROPOS study was halted due to adverse events. Following the news, the firm thinks the ...

In a report released on May 25, Thomas Smith from SVB Securities maintained a Buy rating on Keros Therapeutics (KROS – Research Report), with a price target of $80.00. The company’s shares closed last ...

Fintel reports that on June 10, 2025, B of A Securities downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) from Buy to Neutral. Analyst Price Forecast Suggests 89.41% Upside As of June 2, ...

Keros Therapeutics, Inc. ( (KROS)) has released its Q3 earnings. Here is a breakdown of the information Keros Therapeutics, Inc. presented to its investors. Unlock your investing potential with ...

Keros Therapeutics is ending development of a phase 2 candidate designed to treat high blood pressure in the lungs, a move that has triggered layoffs for 45% of the biotech’s team. The Massachusetts ...